Content area
Full text
Peptor Ltd., a biopharmaceutical firm based in Israel, is soon hoping to enter clinical trials in the U.S. It is also eyeing a run for the public market, a more plausible scenario given the market's recent uptick.
The only thing standing in Peptor's way from coming to the U.S. and getting this drug to market is cash and a partner. "If Peptor had a deal with a large pharmaceutical company it could get to market and even go public. We are close to signing a deal with a U.S.-based company, but far away in terms of months," said Yoram Karmon, president and chief executive of Peptor. He added that the partner will likely be one of the top 20 U.S.-based pharmaceutical firms.
Assuming that the partnership, which is all but done, is made and the mezzanine round comes through,...